치주질환 치료제 시장 규모, 점유율, 동향 분석 리포트 : 질환별, 약물 유형별, 유통 채널별, 지역별, 부문별 예측(2024-2030년)

Periodontal Therapeutics Market Growth & Trends:

The global periodontal therapeutics market size is anticipated to reach USD 1.41 billion by 2030, growing at a CAGR of 7.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing prevalence of periodontal diseases aided by the growing geriatric population. According to an article published by NCBI, in September 2023, the percentage of older adults affected by the disease is anticipated to rise from 42.44% in 2020 to 54.57% by 2050. Mild periodontal diseases are predicted to continue being the most common type, accounting for 80.39% of cases. Additionally, the number of untreated cavities in teeth is expected to increase by 75.2% between 2020 and 2050.

Increasing awareness about oral health fuels the growth of the market. Numerous campaigns have been created using data from formative needs assessments, focusing on the widespread issue of poor dental health in various populations. These initiatives aimed to increase awareness and knowledge about periodontal health, promote self-care dental preventive behaviors, and encourage the utilization of dental health services. Certain campaigns were tailored to specific demographics, including adults, children, parents of infants, and disadvantaged socio-economic groups considered to be at higher risk for dental problems. The Perio-Year Campaign in Norway targeted individuals aged 15 and above to increase awareness. As part of the initiative, dentists received one year of training to reinforce campaign messages during patient consultations. The campaign utilized diverse media channels and distributed informational booklets to grocery stores, pharmacies, and dental offices.

The emergence of antibiotic-resistant strains of bacteria associated with periodontal diseases necessitates several key actions and considerations. For instance, in October 2022, a research study focused on assessing antimicrobial resistance in microorganisms associated with periodontal diseases underscores the importance of ongoing research in understanding the scope of resistance among these bacteria. This investigation highlights the necessity for developing targeted treatments and strategies to address antibiotic resistance effectively.The study emphasizes the detrimental impact of healthcare professionals on antimicrobial resistance due to indiscriminate prescribing of antimicrobials. This emphasizes the significance of adhering to appropriate prescribing practices and the necessity for healthcare providers to possess awareness regarding the resistance patterns of the bacteria they are addressing.

Furthermore, technological advancements in drug development have been significantly influenced by the integration of big data mining, systems biology, and deep learning methods. These advancements aim to enhance the discovery and development of novel drugs for the treatment of the diseases, which are characterized by inflammation and infection in the gums and periodontal tissues. One key methodology involves leveraging big data mining to analyze genome-wide microarray datasets, such as the GSE10334 dataset, which contains data from individuals with moderate to severe periodontitis. This approach enables the identification of candidate genes, protein-protein interaction (PPIN) networks, and regulatory networks (GRNs) involved in the disease process. Applying system identification and system order detection methods, researchers can pinpoint genuine gene-wide gene expression networks (GWGENs) for both diseased and healthy control groups. This step is crucial for elucidating the molecular mechanisms underlying the disease and identifying potential targets for drug development.

Periodontal Therapeutics Market Report Highlights:

• The chronic periodontal disease segment held the largest share of the market in 2023. It can be attributed to the high treatment rate of the disease due to significant discomfort to the patients, high treatment adherence rate, and overall, a growing prevalence of the disease.
• The doxycycline drug type dominated the market in 2023. Doxycycline, even at lower concentrations, has been found to inhibit matrix metalloproteinase-8 (MMP-8), an enzyme abundant in periodontitis.
• Hospital pharmacies distribution channel held the largest share of the market in 2023. The high prescription rates at hospitals, high patient preference of purchase prescribed medications from hospital pharmacies, and increasing number of patients visiting hospitals for periodontal diseases are driving the growth of this segment.
• North America dominated the market owing to factors such as advanced healthcare infrastructure, rising prevalence of the disease, and favorable regulatory environment.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Disease
  • 1.2.2. Drug Type
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Disease and Drug Type outlook
  • 2.2.2. Distribution Channel outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Periodontal Therapeutics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growing prevalence of periodontal diseases
    • 3.2.1.2. Increasing awareness about oral health
    • 3.2.1.3. Rising geriatric population
    • 3.2.1.4. Technological advancements in dentistry
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Limited awareness and education for oral health
    • 3.2.2.2. Stringent regulatory policies
• 3.3. Periodontal Therapeutics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis

Chapter 4. Periodontal Therapeutics Market: Disease Estimates & Trend Analysis

• 4.1. Global Periodontal Therapeutics Market: Disease Dashboard
• 4.2. Global Periodontal Therapeutics Market: Disease Movement Analysis
• 4.3. Global Periodontal Therapeutics Market by Disease, Revenue
• 4.4. Gingivitis
  • 4.4.1. Gingivitis market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Chronic Periodontal Disease
  • 4.5.1. Chronic Periodontal Disease market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Aggressive Periodontal Disease
  • 4.6.1. Aggressive Periodontal Disease market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Periodontal Therapeutics Market: Drug Type Estimates & Trend Analysis

• 5.1. Global Periodontal Therapeutics Market: Drug Type Dashboard
• 5.2. Global Periodontal Therapeutics Market: Drug Type Movement Analysis
• 5.3. Global Periodontal Therapeutics Market by Drug Type, Revenue
• 5.4. Doxycycline
  • 5.4.1. Doxycycline market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Minocycline
  • 5.5.1. Minocycline market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Chlorhexidine
  • 5.6.1. Chlorhexidine market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Metronidazole
  • 5.7.1. Metronidazole market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Other drug types
  • 5.8.1. Other drug types market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Periodontal Therapeutics Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Global Periodontal Therapeutics Market: Distribution Channel Dashboard
• 6.2. Global Periodontal Therapeutics Market: Distribution Channel Movement Analysis
• 6.3. Global Periodontal Therapeutics Market by Distribution Channel, Revenue
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Online Channel
  • 6.6.1. Online Channel market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Periodontal Therapeutics Market: Regional Estimates & Trend Analysis by Disease, Drug Type, and Distribution Channel

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Mexico
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Pfizer Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Lupin Ltd
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Teva Pharmaceuticals USA, Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Sun Pharmaceutical Industries Ltd.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Tokyo Chemical Industry Co., Ltd.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Bausch Health Companies Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. USAntibiotics
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Melinta Therapeutics LLC
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Cipla, Inc.
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Chartwell Pharmaceuticals LLC.
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. benchmarking
    • 8.3.13.4. Strategic initiatives